Pharmacy
Arguments center on Aduhelm's price, its questionable clinical benefit and why the agency is going against FDA approval of the drug.
Currently, Aduhelm, made by Biogen, is the only monoclonal antibody approved by the FDA for the treatment of Alzheimer's disease.
Premiums covered the $56,000 yearly cost of the Alzheimer's drug Aduhelm, but that price has been slashed by 50%.
The maker of Humira wants 340B hospitals to submit requested claims data to a web-based platform.
The agency has determined that the protective health benefits of a single booster dose of the Pfizer shot outweigh the potential risks.
The Supreme Court has fast-tracked oral arguments over federal vaccine mandates by scheduling a special session for Friday, January 7.
The treatment has been cleared for anyone 12 years old and older who is at high risk for severe COVID-19, including hospitalization and death.
The Supreme Court is fast-tracking the cases as the Omicron variant is causing COVID-19 cases to surge nationwide.
When unvaccinated adults are asked what would convince them to get a COVID-19 vaccine, half say nothing.
OIG found gaps between the number of providers authorized to treat patients with medication and the number of those who need care.